NCT04646837 - Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

May 1, 2024

Study Completion Date

March 31, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Durvalumab

Durvalumab 1000 mg IV Q3W for 2 cycle + Followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 1500mg Q4W for 8 months

DRUG

Albumin Paclitaxel

Albumin Paclitaxel 200-260 mg, depending on the patient's physical condition, for 2 cycle

DRUG

Carboplatin/Cisplatin

Carboplatin AUC 6 IV Q3W or Cisplatin 80mg/㎡ for 2 cycle

Trial Locations (1)

100000

RECRUITING

Peking Union Medical College Hospital, Beijing